References:
Uvebrant K., Reimer Rasmusson L., Talts JF., Alberton P., Aszodi A., and Lundgren-Åkerlund E. “Integrin α10β1-selected Equine MSCs have Improved Chondrogenic Differentiation, Immunomodulatory and Cartilage Adhesion Capacity.” Ann Stem Cell Res. 2,001–009 (2019).
Delco ML., Goodale M., Talts JF., Pownder SL., Koff MF., Miller AD., Nixon B., Bonassar LJ., Lundgren-Åkerlund E., and Fortier LA. “Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model.” Am J Sports Med. 48, 612-623 (2020).
Clarke EJ., Johnson E., Caamano Gutierrez E., Andersen C, Berg LC., Jenkins RE., Lindegaard C., Uvebrant K., Lundgren-Åkerlund E., Turlo A., James V., Jacobsen S., and Peffers MJ. “Temporal extracellular vesicle protein changes following intraarticular treatment with integrin α10β1-selected mesenchymal stem cells in equine osteoarthritis.” Front Vet Sci. 9:1057667 (2022).
Andersen C., Jacobsen S., Uvebrant K, Griffin, IV, JF., Vonk LA., Walters M., Berg LC., Lundgren-Åkerlund E., and Lindegaard C. "Integrin α10β1-Selected Mesenchymal Stem Cells Reduce Pain and Cartilage Degradation and Increase Immunomodulation in an Equine Osteoarthritis Model." Cartilage. Jun;16(2):250-264 (2025).
Andersen C., Walters M., Bundgaard L., Berg LC., Vonk LA., Lundgren-Åkerlund E., Lyngfeldt Henriksen B., Lindegaard C., Skovgaard K., and Jacobsen S. “Intraarticular treatment with integrin α10β1-selected mesenchymal stem cells affects microRNA expression in experimental post-traumatic osteoarthritis in horses.” Front Vet Sci. 11:1374681 (2024).
Andersen C, Uvebrant K, Mori Y, Aarsvold S, Jacobsen S, Berg LC, Lundgren-Åkerlund E, Lindegaard C. “Human integrin α10β1-selected mesenchymal stem cells home to cartilage defects in the rabbit knee and assume a chondrocyte-like phenotype.” Stem Cell Res Ther. May 16;13(1):206 (2022).
EQGen Biomedical is based in the US and is the exclusive licensee of a proprietary, next-generation stem cell treatment for equine osteoarthritis and joint disease (EQSTEM® - Xintela AB, Sweden).
The globally patented technology leverages a unique, proprietary method to purify multipotent cell populations using stem cell marker integrin α10β1. Integrin α10β1-selected MSCs cell populations show a superior ability to adhere to damaged cartilage and exposed subchondral bone in explants and reduction in lameness and joint pathology.
EQGen and Xintela are collaborating on clinical development and commercialization of the technology for the treatment of joint disease in equine, canine and camelid patients.
Previous studies of EQSTEM® have shown extremely promising results. In-vitro analyses have demonstrated greater ability to adhere to damaged cartilage and enhanced chondrogenic differentiation ability. Multiple in-vivo studies have been performed, including a 25-patient analysis with post traumatic OA showing reduced cartilage damage and bone sclerosis, reduced pain, and detection of cells at the cartilaginous surface 52 days post injection.
The following link is an interview with Lisa Fortier, DVM, PhD, ACVS discussing results from the Delco et al. preclinical study conducted at Cornell University.
